ReviewExpert review of vaccines2013
HLA ligandome tumor antigen discovery for personalized vaccine approach.
Review in Expert review of vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03871790 (Peptide-based Immunization for Colon- and Pancreas-carcinoma), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide-based Immunization for Colon- and Pancreas-carcinoma (PICOP-GLOBAL): An International, Multicenter Protocol
Who cites it
51 citing papers in PubMed, 90 citations in OpenAlex.
- The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.British journal of cancer · 2023Article
- Trojan-horse silk fibroin nanocarriers loaded with a re-call antigen to redirect immunity against cancer.Journal for immunotherapy of cancer · 2023Article
- Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.Biomedicines · 2022Review
- Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.Journal for immunotherapy of cancer · 2022Article
- Recent Progress on Therapeutic Vaccines for Breast Cancer.Frontiers in oncology · 2022Review
- Evolution of CD8Cells · 2021Review
- Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.Acta pharmaceutica Sinica. B · 2021Review
- Spliced HLA-bound peptides: a Black Swan event in immunology.Clinical and experimental immunology · 2021Review
- HLA Class II Presentation Is Specifically Altered at Elevated Temperatures in the B-Lymphoblastic Cell Line JY.Molecular & cellular proteomics : MCP · 2021Article
- Review
- Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse.Molecular & cellular proteomics : MCP · 2020Article
- Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.Blood cancer journal · 2020Article
- Integrated Process for Capture and Purification of Virus-Like Particles: Enhancing Process Performance by Cross-Flow Filtration.Frontiers in bioengineering and biotechnology · 2020Article
- Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.American journal of cancer research · 2020Review
- Murine xenograft bioreactors for human immunopeptidome discovery.Scientific reports · 2019Article
- Therapeutic vaccine strategies to induce tumor-specific T-cell responses.Bone marrow transplantation · 2019Review
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.Molecular & cellular proteomics : MCP · 2019Article
- Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.Genome medicine · 2019Article
- Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy.Frontiers in molecular biosciences · 2019Review
- Personalized cancer vaccines: adjuvants are important, too.Cancer immunology, immunotherapy : CII · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usually not used in the adult organism. The search for cancer-associated antigens shared by many patients with a particular cancer has yielded a number of hits used in clinical vaccination trials with indication of survival benefit. Targeting cancer-specific antigens, which are exclusively expressed on cancer cells and not on normal cells, holds the promise for much better results and perhaps even a cure. Such antigens, however, may specifically appear in very few patients or may be mutated appearing just in one patient. Therefore, to target these in a molecularly defined way, the approach has to be individualized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.